Influence of activating KIRs, KIR haplotype, KIR B-content score, and inhibiting KIRs on the risk for the development of ALL
| Factor . | ALL patients . | Controls . | OR (95% CI) . | P . |
|---|---|---|---|---|
| KIR2DS1 | ||||
| Yes | 112 (34.1%) | 127 (37.5%) | ||
| No | 216 (65.9%) | 212 (62.5%) | 1.154 (0.842-1.585) | .372 |
| KIR2DS2 | ||||
| Yes | 172 (52.4%) | 180 (53.1%) | ||
| No | 156 (47.6%) | 159 (46.9%) | 1.027 (0.758-1.392) | .865 |
| KIR2DS3 | ||||
| Yes | 107 (32.6%) | 93 (27.4%) | ||
| No | 221 (67.4%) | 246 (72.6%) | 0.781 (0.560-1.088) | .143 |
| KIR2DS4 | ||||
| Yes | 310 (94.5%) | 318 (93.8%) | ||
| No | 18 (5.5%) | 21 (6.2%) | 0.879 (0.460-1.681) | .698 |
| KIR2DS5 | ||||
| Yes | 103 (31.4%) | 103 (30.4%) | ||
| No | 225 (68.6%) | 236 (69.6%) | 0.952 (0.686-1.323) | .776 |
| KIR3DS1 | ||||
| Yes | 122 (37.2%) | 126 (37.2%) | ||
| No | 206 (62.8% | 213 (62.8%) | 0.999 (0.730-1.368) | .993 |
| KIR haplotype | ||||
| A | 88 (26.8%) | 103 (30.4%) | ||
| B | 240 (73.2%) | 236 (69.6%) | 0.8401 (0.600-1.176) | .3103 |
| B-content score | ||||
| 0 | 96 (29.3%) | 103 (30.4%) | ||
| 1 | 128 (39.0%) | 134 (39.5%) | ||
| 2 | 81 (24.7%) | 79 (23.3%) | .313 | |
| 3 | 21 (6.4%) | 19 (5.6%) | ||
| 4 | 2 (0.6%) | 4 (1.2%) | ||
| KIR2DL1 | ||||
| Yes | 313 (95.4%) | 333 (98.2%) | ||
| No | 15 (4.6%) | 6 (1.8%) | 24.139 (1.018-6.941) | .046 |
| KIR2DL2 | ||||
| Yes | 176 (53.7%) | 178 (52.5%) | ||
| No | 152 (46.3%) | 161 (47.5%) | 0.955 (0.703-1.293) | .766 |
| KIR2DL3 | ||||
| Yes | 287 (87.5%) | 303 (89.4%) | ||
| No | 41 (12.5%) | 36 (10.6%) | 1.201 (0.746-1.934) | .448 |
| KIR2DL4 | ||||
| Yes | 328 (100%) | 339 (100%) | ||
| No | 0 (0%) | 0 (0%) | 1.033 (0.02-52.241) | .987 |
| KIR2DL5 | ||||
| Yes | 183 (55.8%) | 176 (51.9%) | ||
| No | 145 (44.2%) | 163 (48.1%) | 0.856 (0.631-1.160) | .316 |
| KIR3DL1 | ||||
| Yes | 312 (95.1%) | 323 (95.2%) | ||
| No | 16 (4.9%) | 16 (4.7%) | 0.744 (0.363-1.518) | .416 |
| KIR3DL2 | ||||
| Yes | 328 (100%) | 338 (99.7%) | ||
| No | 0 (0%) | 1 (0.3%) | 0.344 (0.014-8.463) | .512 |
| KIR3DL3 | ||||
| Yes | 313 (95.4%) | 328 (96.8%) | ||
| No | 15 (4.6%) | 11 (3.2%) | 1.428 (0.645-3.158) | .378 |
| KIR2DP1 | ||||
| Yes | 320 (97.6%) | 337 (99.4%) | ||
| No | 8 (2.4%) | 2 (0.59%) | 4.213 (0.888-19.988) | .070 |
| KIR2DP1f1 | ||||
| Yes | 105 (32.01%) | 115 (33.9%) | ||
| No | 223 (67.99%) | 224 (66.08%) | 1.090 (0.788-1.505) | .599 |
| KIR2DP1f2 | ||||
| Yes | 305 (93%) | 324 (95.5%) | ||
| No | 23 (7%) | 15 (4.4%) | 1.629 (0.833-3.180) | .153 |
| Factor . | ALL patients . | Controls . | OR (95% CI) . | P . |
|---|---|---|---|---|
| KIR2DS1 | ||||
| Yes | 112 (34.1%) | 127 (37.5%) | ||
| No | 216 (65.9%) | 212 (62.5%) | 1.154 (0.842-1.585) | .372 |
| KIR2DS2 | ||||
| Yes | 172 (52.4%) | 180 (53.1%) | ||
| No | 156 (47.6%) | 159 (46.9%) | 1.027 (0.758-1.392) | .865 |
| KIR2DS3 | ||||
| Yes | 107 (32.6%) | 93 (27.4%) | ||
| No | 221 (67.4%) | 246 (72.6%) | 0.781 (0.560-1.088) | .143 |
| KIR2DS4 | ||||
| Yes | 310 (94.5%) | 318 (93.8%) | ||
| No | 18 (5.5%) | 21 (6.2%) | 0.879 (0.460-1.681) | .698 |
| KIR2DS5 | ||||
| Yes | 103 (31.4%) | 103 (30.4%) | ||
| No | 225 (68.6%) | 236 (69.6%) | 0.952 (0.686-1.323) | .776 |
| KIR3DS1 | ||||
| Yes | 122 (37.2%) | 126 (37.2%) | ||
| No | 206 (62.8% | 213 (62.8%) | 0.999 (0.730-1.368) | .993 |
| KIR haplotype | ||||
| A | 88 (26.8%) | 103 (30.4%) | ||
| B | 240 (73.2%) | 236 (69.6%) | 0.8401 (0.600-1.176) | .3103 |
| B-content score | ||||
| 0 | 96 (29.3%) | 103 (30.4%) | ||
| 1 | 128 (39.0%) | 134 (39.5%) | ||
| 2 | 81 (24.7%) | 79 (23.3%) | .313 | |
| 3 | 21 (6.4%) | 19 (5.6%) | ||
| 4 | 2 (0.6%) | 4 (1.2%) | ||
| KIR2DL1 | ||||
| Yes | 313 (95.4%) | 333 (98.2%) | ||
| No | 15 (4.6%) | 6 (1.8%) | 24.139 (1.018-6.941) | .046 |
| KIR2DL2 | ||||
| Yes | 176 (53.7%) | 178 (52.5%) | ||
| No | 152 (46.3%) | 161 (47.5%) | 0.955 (0.703-1.293) | .766 |
| KIR2DL3 | ||||
| Yes | 287 (87.5%) | 303 (89.4%) | ||
| No | 41 (12.5%) | 36 (10.6%) | 1.201 (0.746-1.934) | .448 |
| KIR2DL4 | ||||
| Yes | 328 (100%) | 339 (100%) | ||
| No | 0 (0%) | 0 (0%) | 1.033 (0.02-52.241) | .987 |
| KIR2DL5 | ||||
| Yes | 183 (55.8%) | 176 (51.9%) | ||
| No | 145 (44.2%) | 163 (48.1%) | 0.856 (0.631-1.160) | .316 |
| KIR3DL1 | ||||
| Yes | 312 (95.1%) | 323 (95.2%) | ||
| No | 16 (4.9%) | 16 (4.7%) | 0.744 (0.363-1.518) | .416 |
| KIR3DL2 | ||||
| Yes | 328 (100%) | 338 (99.7%) | ||
| No | 0 (0%) | 1 (0.3%) | 0.344 (0.014-8.463) | .512 |
| KIR3DL3 | ||||
| Yes | 313 (95.4%) | 328 (96.8%) | ||
| No | 15 (4.6%) | 11 (3.2%) | 1.428 (0.645-3.158) | .378 |
| KIR2DP1 | ||||
| Yes | 320 (97.6%) | 337 (99.4%) | ||
| No | 8 (2.4%) | 2 (0.59%) | 4.213 (0.888-19.988) | .070 |
| KIR2DP1f1 | ||||
| Yes | 105 (32.01%) | 115 (33.9%) | ||
| No | 223 (67.99%) | 224 (66.08%) | 1.090 (0.788-1.505) | .599 |
| KIR2DP1f2 | ||||
| Yes | 305 (93%) | 324 (95.5%) | ||
| No | 23 (7%) | 15 (4.4%) | 1.629 (0.833-3.180) | .153 |
CI, confidence interval; OR, odds ratio.